CIRC Wins NMPA Nod for Clinical Trials of BNCT Boron Drug for Resistant Head and Neck Tumors

China Isotope & Radiation Corp. ( (HK:1763) ) has shared an announcement.

China Isotope & Radiation Corporation announced that its subsidiary, Shenzhen Zhonghe Headway Bio-Sci & Tech, has received approval from China’s National Medical Products Administration to begin clinical trials for its independently developed BNCT boron drug, Borofalan (10B) for Injection. The drug is designed for difficult-to-treat head and neck tumors that are resistant to conventional radiotherapy and chemotherapy, offering a short treatment course of one to two sessions with low toxicity and side effects, reflecting a cutting-edge approach in precision oncology. The clinical trial approval represents a key milestone in Zhonghe Headway’s integrated drug-device BNCT program, moving the project into the clinical translation phase and strengthening CIRC’s position in advanced nuclear medicine while aligning with China’s broader “Healthy China” strategy and ambitions to provide a domestic, globally relevant solution for tumor treatment.

The most recent analyst rating on (HK:1763) stock is a Buy with a HK$25.00 price target. To see the full list of analyst forecasts on China Isotope & Radiation Corp. stock, see the HK:1763 Stock Forecast page.

More about China Isotope & Radiation Corp.

China Isotope & Radiation Corporation (CIRC) is a PRC-incorporated joint stock company listed in Hong Kong that operates in the nuclear technology and isotopes sector, with a focus on medical applications. Through subsidiaries such as Shenzhen Zhonghe Headway Bio-Sci & Tech, it develops radiopharmaceuticals and advanced radiation-based therapies aimed at precision oncology and tumor treatment in China and internationally.

Average Trading Volume: 367,490

Technical Sentiment Signal: Buy

Current Market Cap: HK$6.63B

For a thorough assessment of 1763 stock, go to TipRanks’ Stock Analysis page.